Logo image of ACOR

ACORDA THERAPEUTICS INC (ACOR) Stock Fundamental Analysis

NASDAQ:ACOR - Nasdaq - US00484M7002 - Common Stock - Currency: USD

0.661  -0.22 (-24.86%)

After market: 0.5656 -0.1 (-14.43%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ACOR. ACOR was compared to 571 industry peers in the Biotechnology industry. ACOR has a bad profitability rating. Also its financial health evaluation is rather negative. ACOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACOR had negative earnings in the past year.
In the past year ACOR has reported a negative cash flow from operations.
ACOR had negative earnings in each of the past 5 years.
In the past 5 years ACOR always reported negative operating cash flow.
ACOR Yearly Net Income VS EBIT VS OCF VS FCFACOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

The Return On Assets of ACOR (-233.00%) is worse than 90.78% of its industry peers.
Industry RankSector Rank
ROA -233%
ROE N/A
ROIC N/A
ROA(3y)-90.83%
ROA(5y)-64.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOR Yearly ROA, ROE, ROICACOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

ACOR has a Gross Margin of 86.92%. This is amongst the best in the industry. ACOR outperforms 90.61% of its industry peers.
In the last couple of years the Gross Margin of ACOR has grown nicely.
The Profit Margin and Operating Margin are not available for ACOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y1.97%
ACOR Yearly Profit, Operating, Gross MarginsACOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

ACOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACOR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACOR has been increased compared to 5 years ago.
Compared to 1 year ago, ACOR has a worse debt to assets ratio.
ACOR Yearly Shares OutstandingACOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
ACOR Yearly Total Debt VS Total AssetsACOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

ACOR has an Altman-Z score of -16.36. This is a bad value and indicates that ACOR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACOR (-16.36) is worse than 83.28% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.36
ROIC/WACCN/A
WACC5.57%
ACOR Yearly LT Debt VS Equity VS FCFACOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

ACOR has a Current Ratio of 0.33. This is a bad value and indicates that ACOR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.33, ACOR is not doing good in the industry: 96.42% of the companies in the same industry are doing better.
A Quick Ratio of 0.26 indicates that ACOR may have some problems paying its short term obligations.
ACOR has a worse Quick ratio (0.26) than 97.61% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.26
ACOR Yearly Current Assets VS Current LiabilitesACOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ACOR have decreased strongly by -129.75% in the last year.
ACOR shows a decrease in Revenue. In the last year, the revenue decreased by -0.77%.
Measured over the past years, ACOR shows a very negative growth in Revenue. The Revenue has been decreasing by -24.24% on average per year.
EPS 1Y (TTM)-129.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1202.02%
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y-8.39%
Revenue growth 5Y-24.24%
Sales Q2Q%20.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOR Yearly Revenue VS EstimatesACOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M
ACOR Yearly EPS VS EstimatesACOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ACOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOR Price Earnings VS Forward Price EarningsACOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

97.95% of the companies in the same industry are more expensive than ACOR, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.69
ACOR Per share dataACOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 -100 -150 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACOR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACORDA THERAPEUTICS INC

NASDAQ:ACOR (4/11/2024, 8:00:01 PM)

After market: 0.5656 -0.1 (-14.43%)

0.661

-0.22 (-24.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-07 2024-03-07/amc
Earnings (Next)05-02 2024-05-02/amc
Inst Owners0.49%
Inst Owner Change0%
Ins Owners44.4%
Ins Owner Change0%
Market Cap821.03K
Analysts82.86
Price Target10.2 (1443.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 8.69
EPS(TTM)-204.57
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-11.47
FCFYN/A
OCF(TTM)-11.26
OCFYN/A
SpS94.75
BVpS-127.17
TBVpS-145.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -233%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.92%
FCFM N/A
ROA(3y)-90.83%
ROA(5y)-64.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y1.97%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 0.83%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.26
Altman-Z -16.36
F-Score4
WACC5.57%
ROIC/WACCN/A
Cap/Depr(3y)0.58%
Cap/Depr(5y)54.73%
Cap/Sales(3y)0.15%
Cap/Sales(5y)10.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1202.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y-8.39%
Revenue growth 5Y-24.24%
Sales Q2Q%20.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y61.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.09%
OCF growth 3YN/A
OCF growth 5YN/A